News

Patients with irritable bowel syndrome more frequently self-reported non-celiac gluten sensitivity compared to the control group, as well as major gastrointestinal symptoms found in the study included bloating, abdominal discomfort, and belching.

In recent years, researchers and advocates have vocalized increasing psychological support for patients with psoriasis.

The primary endpoint of improving near vision without compromising distance vision at Day 14, Hour 9 was met.

Dr. Karan Lal offers insights into diagnosing various forms of rosacea as well as common treatment methods.

Don't Miss a Beat hosts Drs. Vaduganathan and Greene provide insight into the results of trials from ACC.22 late-breaking sessions they highlighted in the preview episode they recorded ahead of the American College of Cardiology's 71st Annual Scientific Session.

In an interview, Karen Kozarsky, CSO of SwanBio discusses the new data being presented at AAN on AAV-based gene therapy candidate SBT101.

At the AAN 2022 Annual Meeting, SwanBio presents new data regarding lead candidate SBT101 for treating adrenomyeloneuropathy, a rare debilitating disease with no approved therapies.

National registry data suggest management and outcomes of ST-elevation myocardial infarction are returning to pre-pandemic levels, though vaccinated patients have fared better in mortality.

Data from PROMPT-HF show clinicians are more likely to add 1 of 4 topline drug classes to a patient's HFrEF regimen when alerted on the opportunity.

Mikhail Kosiborod, MD, discusses EMPULSE findings supporting hospital-stage treatment with the SGLT-2—regardless of patients' diabetes status.

Peter Sogaard discusses the benefit of monitoring for arrhythmias in patients with non-STEMI heart attacks and the need to look at arrhythmias in a different light.

Deepak Bhatt, MD, MPH, breaks down data from the SCORED trial presented at ACC.22, which demonstrated sotagliflozin provided significant benefit in terms of reducing total MACE, total MI, and total stroke, regardless of whether a patient had a history of cardiovascular disease.

Paul M. Ridker, MD, discusses the latest findings from the canakinumab trial before highlighting his team's work with ziltevekimab in ZEUS.

Dr. Butler discusses findings from the FIDELITY analyses on the consistent benefits of finerenone, regardless of ASCVD history in patients with CKD and T2D.

A discussion into broadening the findings of the SuperWIN trial and its potential effects on a larger, more at-risk population.

Dylan Steen, MD discusses positive findings from the trial on links between personalized education and DASH diet adherence.

Dupilumab is the only biologic medicine to show positive, clinically meaningful phase 3 results in adults and adolescents 12 years and older with EoE.

This is the first topical treatment approved by the FDA for facial angiofibroma associated with tuberous sclerosis complex in adults and children 6 years and older.

Steve Nissen, MD, reviews the promising phase 1 APOLLO findings, and details what needs to be investigated next for the siRNA.

Dr. Rafael Pérez-Figueroa talks about how the pandemic has exacerbated racial inequities on multiple levels saying that people of color have been overrepresented in jobs with high exposure to COVID-19, leading to disproportionate infections and death.

Once a day readings over a year would detect 98.3% of the first Afib >24 hour episodes, while the probability of ≥1 false positive reading would be 98%.

Deepak L. Bhatt, MD, MPH, reviews the latest phase 2b trial data supporting the fast-acting monoclonal antibody infusion for bleeding risk reversal.

VOYAGER PAD subgroup analyses showed the anticoagulant reduced likelihood of hospitalization without increasing bleeding risk in patients with CKD.

Lead SODIUM-HF investigator Justin Ezekowitz provides insight into the trial and why dietary interventions may still be important for heart failure care.

Study author Brian Bergmark, MD, discusses what's next for the ANGTYL3 inhibitor, as well as promising developments in lipid-targeting therapies.

Larry Allen, MD, discusses some of ACC 2022's biggest contributions toward improving evidence-based care to patients with HF.

The majority of patients with HFrEF and RAASi-related hyperkalemia achieved optimal doses of RAASi when treated with patiromer.

No difference in the primary outcome was observed between those randomized to influenza vaccine compared to placebo.